Cite
Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study
MLA
Fraticelli, Paolo, et al. “Low-Dose Oral Imatinib in the Treatment of Systemic Sclerosis Interstitial Lung Disease Unresponsive to Cyclophosphamide: A Phase II Pilot Study.” Arthritis Research & Therapy (Formerly Arthritis Research), vol. 16, no. 4, Aug. 2014, pp. 1–10. EBSCOhost, https://doi.org/10.1186/ar4606.
APA
Fraticelli, P., Gabrielli, B., Pomponio, G., Valentini, G., Bosello, S., Riboldi, P., Gerosa, M., Faggioli, P., Giacomelli, R., Del Papa, N., Gerli, R., Lunardi, C., Bombardieri, S., Malorni, W., Corvetta, A., Moroncini, G., & Gabrielli, A. (2014). Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Research & Therapy (Formerly Arthritis Research), 16(4), 1–10. https://doi.org/10.1186/ar4606
Chicago
Fraticelli, Paolo, Barbara Gabrielli, Giovanni Pomponio, Gabriele Valentini, Silvia Bosello, Piersandro Riboldi, Maria Gerosa, et al. 2014. “Low-Dose Oral Imatinib in the Treatment of Systemic Sclerosis Interstitial Lung Disease Unresponsive to Cyclophosphamide: A Phase II Pilot Study.” Arthritis Research & Therapy (Formerly Arthritis Research) 16 (4): 1–10. doi:10.1186/ar4606.